The company said, “The Company projects revenue for the full year 2026 to be in the range of $410 to $430 million, which represents growth of 26% to 32% over the Company’s 2025 revenue guidance range.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics reports Q3 EPS (38c), consensus (42c)
- Procept BioRobotics backs FY25 revenue view $325.5M, consensus $326.53M
- PRCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?
- Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment